Semax

Semax (ACTH(4-10) analogue) is a heptapeptide. The HEIVE catalog describes it as: A Russian-registered nootropic used clinically for stroke recovery; raises BDNF in animal and some human work. It is also known as ACTH(4-10).

HEIVE groups Semax under focus, memory, mental clarity, mental fatigue and learning. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Semax under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval. Separately, Peptogen publishes Russian registration documentation for Semax 1% nasal drops (PN000812/01). This does not validate injectable research products.

• FDA product data (October 6, 2026)
• FDA compounding safety information
• Manufacturer Semax 1% instruction

The HEIVE editorial risk summary for Semax lists: Occasional over-stimulation at higher doses. Longer-term concerns: Twenty years of clinical use with no signal, though outside Russia the data is hard to audit. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Semax has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Semax: 300 mcg subcutaneous, daytime. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Semax as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists a nasal form for Semax. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of Semax depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Semax depends on the specific formulation (injectable and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Semax: Effects blunt after 3–4 weeks of daily use. Cycling restores them. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Semax and Adamax share the catalog categories neuroplasticity, learning and memory. Semax: A Russian-registered nootropic used clinically for stroke recovery; raises BDNF in animal and some human work. Adamax: A Semax molecule with an adamantane cage bolted on, sold on the claim that the change makes it last longer and push BDNF harder. Almost nothing about it has been published. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Adamax

The HEIVE editorial summary highlights: Stroke trials found the benefit held at 12 months, past the window anyone expected. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.